Financial Analysis: Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and IPSEN (OTCMKTS:IPSEY)

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and IPSEN (OTCMKTS:IPSEY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Greenland Mines Ltd. Common Stock and IPSEN, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1	0	0	0	1.00
IPSEN	1	2	2	0	2.20

Valuation and Earnings

This table compares Greenland Mines Ltd. Common Stock and IPSEN”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55 million	($0.32)	-0.91
IPSEN	$4.16 billion	3.54	$501.78 million	N/A	N/A

IPSEN has higher revenue and earnings than Greenland Mines Ltd. Common Stock.

Risk and Volatility

Greenland Mines Ltd. Common Stock has a beta of 6.97, suggesting that its stock price is 597% more volatile than the S&P 500. Comparatively, IPSEN has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.

Insider & Institutional Ownership

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Greenland Mines Ltd. Common Stock and IPSEN’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
IPSEN	N/A	N/A	N/A

Summary

IPSEN beats Greenland Mines Ltd. Common Stock on 6 of the 9 factors compared between the two stocks.

About Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

About IPSEN

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.